IL290882B2 - Pyrazole compounds, formulations thereof and methods of using the compounds and/or formulations - Google Patents

Pyrazole compounds, formulations thereof and methods of using the compounds and/or formulations

Info

Publication number
IL290882B2
IL290882B2 IL290882A IL29088222A IL290882B2 IL 290882 B2 IL290882 B2 IL 290882B2 IL 290882 A IL290882 A IL 290882A IL 29088222 A IL29088222 A IL 29088222A IL 290882 B2 IL290882 B2 IL 290882B2
Authority
IL
Israel
Prior art keywords
pyrazol
compound
difluoropyridin
ethoxycyclohexyl
salt
Prior art date
Application number
IL290882A
Other languages
English (en)
Hebrew (he)
Other versions
IL290882B1 (en
IL290882A (en
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of IL290882A publication Critical patent/IL290882A/en
Publication of IL290882B1 publication Critical patent/IL290882B1/en
Publication of IL290882B2 publication Critical patent/IL290882B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL290882A 2019-08-30 2020-08-28 Pyrazole compounds, formulations thereof and methods of using the compounds and/or formulations IL290882B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894547P 2019-08-30 2019-08-30
PCT/US2020/048528 WO2021041898A1 (en) 2019-08-30 2020-08-28 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Publications (3)

Publication Number Publication Date
IL290882A IL290882A (en) 2022-04-01
IL290882B1 IL290882B1 (en) 2025-11-01
IL290882B2 true IL290882B2 (en) 2026-03-01

Family

ID=72473975

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290882A IL290882B2 (en) 2019-08-30 2020-08-28 Pyrazole compounds, formulations thereof and methods of using the compounds and/or formulations

Country Status (21)

Country Link
US (3) US11370787B2 (cg-RX-API-DMAC10.html)
EP (1) EP4003990A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022545542A (cg-RX-API-DMAC10.html)
CN (2) CN121159524A (cg-RX-API-DMAC10.html)
AR (1) AR119857A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020335903B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022003564A2 (cg-RX-API-DMAC10.html)
CA (1) CA3152264A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022002993A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220085A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000047A (cg-RX-API-DMAC10.html)
EC (1) ECSP22014379A (cg-RX-API-DMAC10.html)
IL (1) IL290882B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20220050A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022002292A (cg-RX-API-DMAC10.html)
PE (1) PE20220970A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550466A1 (cg-RX-API-DMAC10.html)
PY (1) PY2049213A (cg-RX-API-DMAC10.html)
SA (1) SA522431791B1 (cg-RX-API-DMAC10.html)
TW (1) TWI870449B (cg-RX-API-DMAC10.html)
WO (1) WO2021041898A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545542A (ja) 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
WO2022187303A1 (en) * 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
EP4399208A4 (en) * 2021-09-08 2025-07-16 Rigel Pharmaceuticals Inc IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE CONDITIONS ASSOCIATED WITH RESPIRATORY VIRUS INFECTION
ES3075943T3 (en) * 2022-03-23 2026-08-10 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2026122888A1 (en) * 2024-12-06 2026-06-11 Rigel Pharmaceuticals, Inc. Pharmaceutical compositions comprising 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol -4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate or its salts
US20260159538A1 (en) * 2024-12-06 2026-06-11 Rigel Pharmaceuticals, Inc. Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate and salts thereof, and their pharmaceutical compositions and uses
US20260158048A1 (en) 2024-12-06 2026-06-11 Rigel Pharmaceuticals, Inc. Methods of treatment
CN119950825B (zh) * 2025-03-13 2025-07-22 北京工业大学 基于压电驱动的自适应释药电纺覆膜气管支架的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172560A1 (en) * 2015-04-22 2016-10-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
US8987309B2 (en) 2009-04-17 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
EP2243481A1 (en) 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
CA2794801C (en) 2010-04-07 2019-01-15 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
WO2012072685A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN103347873A (zh) 2011-02-09 2013-10-09 日产化学工业株式会社 吡唑衍生物和有害生物防除剂
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
TW201728592A (zh) 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Ｉｒａｋ抑制劑及其用途
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
JP6483624B2 (ja) 2013-02-07 2019-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリダジノン−アミド誘導体
ES2639717T3 (es) 2013-02-07 2017-10-30 Merck Patent Gmbh Derivados de piridazinona macrocíclicos
ES2728403T3 (es) 2014-01-09 2019-10-24 Merck Patent Gmbh Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK
LT3221306T (lt) 2014-11-20 2020-03-10 Merck Patent Gmbh Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
CN110099899B (zh) * 2016-10-26 2024-01-02 里格尔药品股份有限公司 用作irak抑制剂的噁唑衍生物及其制备方法
JP2022545542A (ja) * 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172560A1 (en) * 2015-04-22 2016-10-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds

Also Published As

Publication number Publication date
AU2020335903B2 (en) 2026-06-11
TWI870449B (zh) 2025-01-21
US20230399326A1 (en) 2023-12-14
PH12022550466A1 (en) 2023-03-06
JP2026053335A (ja) 2026-03-25
CN121159524A (zh) 2025-12-19
US12441723B2 (en) 2025-10-14
JOP20220050A1 (ar) 2023-01-30
SA522431791B1 (ar) 2025-04-14
IL290882B1 (en) 2025-11-01
PE20220970A1 (es) 2022-06-10
BR112022003564A2 (pt) 2022-05-17
MX2022002292A (es) 2022-06-02
CA3152264A1 (en) 2021-03-04
CN114364674A (zh) 2022-04-15
US20210061798A1 (en) 2021-03-04
IL290882A (en) 2022-04-01
US11370787B2 (en) 2022-06-28
WO2021041898A1 (en) 2021-03-04
US20220306620A1 (en) 2022-09-29
PY2049213A (es) 2021-05-05
DOP2022000047A (es) 2022-04-29
ECSP22014379A (es) 2022-05-31
JP2022545542A (ja) 2022-10-27
KR20220054626A (ko) 2022-05-03
CN114364674B (zh) 2025-10-03
AR119857A1 (es) 2022-01-19
CR20220085A (es) 2022-04-19
EP4003990A1 (en) 2022-06-01
TW202122393A (zh) 2021-06-16
AU2020335903A1 (en) 2022-03-24
CO2022002993A2 (es) 2022-04-19

Similar Documents

Publication Publication Date Title
IL290882A (en) Pyrazole compounds, their formulations and methods of using the compounds and/or formulations
IL290780B1 (en) RIP1 inhibitory compounds and methods for their preparation and use
ZA202007486B (en) Rip1 inhibitory compounds and methods for making and using the same
ZA202007487B (en) Rip1 inhibitory compounds and methods for making and using the same
IL290781A (en) rip1 inhibitory compounds and methods for their preparation and use
SG11202103781TA (en) Products, uses & methods
IL285204A (en) Formulation of apavicin, method for its preparation
GB202112727D0 (en) Application for letters patent
ES3065178T3 (en) Biocidal polyamide-compositions, methods for preparing the same and uses thereof
IL285256A (en) A microdroplet manipulation method
GB202015822D0 (en) 66.123.142648/01
GB201912021D0 (en) Methods, products & Uses relating thereto
ZA202204747B (en) D-amphetamine compounds, compositions, and processes for making and using the same
DK3702546T3 (en) Affaldsfrit, snitfrit sammensat træpanel til en træbygningskonstruktion
PT3545753T (pt) Um sistema de plantio e um método para montar o sistema de plantio
IL289141A (en) Compounds 7,8 dihydro-4h-pyrazolo[3,4-c]azepin-6-one
HK40071676A (en) Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
GB202011508D0 (en) .
EP3835313A4 (en) METHOD FOR PREPARING GLY-T?4
CA3034052A1 (fr) Etrier
HK40079639A (en) D-amphetamine compounds, compositions, and processes for making and using the same
HK40079286A (en) D-amphetamine compounds, compositions, and processes for making and using the same
GB202009556D0 (en) .
GB201904278D0 (en) Laser 3.1
GB201904283D0 (en) Laser 3.2